William E. Paul Lecture
This annual lecture, begun in 2016 and part of the Wednesday Afternoon Lecture Series, honors the legacy of Dr. William E. Paul. Dr. Paul was the leader of the NIH immunology community, and his career is without parallel in the field of immunology.
Investigation of the basic mechanisms by which cytokines and interferons exert their effect led to the discovery of a new paradigm in cell signaling, namely the JAK-STAT pathway. These discoveries revealed a remarkably direct mode of regulating gene expressing but also provided insights into mechanisms of human disease and impetus to generate a new class of therapeutic agents. With new tools, it has also become clearer that cytokines and interferons have a profound epigenomic impact, and they themselves have complex genomic organization.
Dr. Nussenzweig will speak about the development of antibody responses focusing on neutralizing antibody responses to SARS-CoViD-2. Over a decade ago, the Nussenzweig laboratory developed methods for rapid antibody cloning from humans in order to understand humoral immune responses to pathogens beginning with HIV-1. These methods have been widely adapted by others facilitating antibody cloning for multiple human pathogens and their clinical development.
Phylogenetic studies indicate that T cells and B cells have been constant companions in vertebrates for more than 500 million years. For antigen recognition, however, lymphocytes in the jawless vertebrates (lampreys and hagfish) use variable lymphocyte receptors that are composed of leucine-rich repeat sequences instead of immunoglobulin V(D)J and C domains. Convergent evolution may account for these alternative solutions to achieve specific adaptive immunity.
While inbred mice have been a very powerful model for analyzing the immune system, recent advances, both technological and conceptual, have begun to make direct studies of the human immune system possible. This is vitally important from a translational perspective, as mouse models of disease have not been as productive as hoped for in producing “actionable intelligence” with which to diagnose and treat patients.
The two faces of the IL-15- Janus Kinase-Stat system: implications for the immunotherapy of autoimmune diseases and cancer
Dr. Walmann will present the annual William Paul lecture. Dr. Waldmann defined the IL-2 receptor alpha and beta subunits using the daclizumab antibody he discovered, an antibody that is approved by the FDA. He co-discovered IL-15 and performed the first in-human clinical trial with this agent in patients with malignancy. Furthermore, Waldmann defined molecular abnormalities of the common gamma cytokine, Jak/Stat signaling pathway in HTLV-1 associated adult T-cell lymphoma and translated this discovery with a trial of a Jak inhibitor in patients with this disorder.
Dr. Glimcher is President and CEO of Dana-Farber Cancer Institute, Principal Investigator and Director of Dana-Farber/Harvard Cancer Center and the proposed Richard and Susan Smith Professor of Medicine at Harvard Medical School. Previously, she was the Stephen and Suzanne Weiss Dean and Professor of Medicine of Weill Cornell Medical College in New York City, and Provost for Medical Affairs of Cornell University. Prior to her work at Cornell, Dr.
The page was last updated on Wednesday, December 8, 2021 - 7:19pm